Actively Recruiting
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2024-12-24
20
Participants Needed
1
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the GBM patient.GBM histologically appears to be a tumor of vascular origin characterized by necrosis and microvascular proliferation, and neoangiogenesis is a key factor in the growth and poor prognosis of GBM. Bevacizumab can inhibit the biological effects of VEGF, including the permeability and proliferation of blood vessels, as well as the migration and survival of endothelial cells, so as to inhibit tumor angiogenesis, growth and metastasis. The aim of this study is to evaluate the efficacy and safety of bevacizumab in the preoperative adjuvant treatment of patients with new-onset high-grade gliomas.
CONDITIONS
Official Title
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 2 18 years or older
- Male or female
- Imaging diagnosis of high-grade glioma
- Karnofsky Performance Status (KPS) score of 60 or higher
You will not qualify if you...
- Previous treatment with anti-angiogenic targeted drugs
- Serious cardiac, pulmonary, hepatic, or renal disease
- History of arterial or venous blood clots within 6 months before screening
- Infectious diseases such as tuberculosis or viral hepatitis
- Uncontrolled high blood pressure, bleeding disorders, or unhealed wounds or fractures
- History of psychotropic substance abuse that cannot be stopped or mental disorders
- Abnormal blood clotting with bleeding tendency
- Conditions that make participation unsuitable, such as pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Actively Recruiting
Research Team
J
Junkuan Wang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here